

FDA Foreign Drug Inspection Program: A System at Risk

HEARING

FDA Foreign Drug Inspection Program: A System at Risk

Subcommittee on Oversight and Investigations
Thursday, November 1, 2007, 10:00 a.m.
2123 Rayburn House Office Building

Hearing Webcast

(Any use of this recording is subject to Rule XI, 4 of the House of Representatives. See text of Rule XI, 4 as posted by the House Committee on Rules.)

Connect to the Archived Video Webcast of this Hearing (280 kbps) or Download
Windows Media Player is required to view Committee Web casts.
Note: A version for Mac users is available on Microsoft's Web site.

Witness List & Prepared Testimony

Please click on the name of the witness to link to their prepared testimony. The testimony is available in Adobe pdf file format.

Panel I

Marcia G. Crosse, Ph.D.
Director, Health Care
U.S. Government Accountability Office
441 G Street, NW, Room 5K21
Washington, DC 20548

Drug Safety Findings by the GAO Power Point

Mr. William Hubbard
Senior Advisor
Coalition for a Stronger FDA
202 Weaver Mine Trail
Chapel Hill, NC 27517

Ben England, Esq.
Special Counsel
Jones, Walker, Waechter, Poitevent, Carr & Denzgre, L.L.P.
The Watergate
2600 Virginia Avenue, NW, Suite 1113
Washington, DC 20037
Mr. Carl R. Nielsen

Director (Retired)
Division of Import Operations
Office of Regulatory Affairs
Food and Drug Administration

Panel II

John Dubeck, Esq.
Partner
Keller and Heckman, LLP
And
Counsel
Bulk Pharmaceuticals Taskforce
Synthetic Organic Chemical Manufacturers Association
1001 G Street, NW, Suite 500 West
Washington, DC 20001

Mr. Bruce Downey
Chairman and CEO
Barr Pharmaceuticals, Inc.
And
Chairman
Generic Pharmaceutical Association
25 Massachusetts Avenue, NW, Suite 440
Washington, DC 20001

Mr. Guido Villax
Immediate Past Chairman
Pharmaceuticals Business Committee
Member of the Board of Directors
European Fine Chemicals Group
(A CEFIC Sector Group)
Brussels, Belgium
And
Chief Executive Officer
Hovione FarmaCiencia SA
SeteCasas
2674-506 Loures
Portugal

Panel III

The Honorable Andrew C. von Eschenbach, M.D.
Commissioner
Food and Drug Administration
U.S. Department of Health and Human Services
5600 Fishers Lane
Rockville, MD 20857

Accompanied by
Ms. Margaret O'K. Glavin
Associate Commissioner for Regulatory Affairs
Food and Drug Administration
U.S. Department of Health and Human Services
5600 Fishers Lane
Rockville, MD 20857

Supplementary Documents:

- "FDA Foreign Drug Inspection Program: A System At Risk" -- October 30, 2007 Committee Staff Report
- FDA Foreign Inspections -- Power Point by Chairman Stupak
- "Foreign Drugs Get Little Scrutiny by FDA" -- November 1, 2007 AP article
- "FDA's Foreign Inspection Budget Lean" -- November 1, 2007 Washington Post article
- "Chinese Chemicals Flow Unchecked Onto World Drug Market" -- October 31, 2007 New York Times article

Hearing Transcript

Not available at this time. The printed hearing should be available within 90-120 days of the conclusion of the hearing. When available, the text of the printed hearing may be viewed at the U.S. Government Printing Office Web site.